following an Independent Review Panel Assessment:
ranolazine (Ranexa®) is not recommended for use within NHS Scotland.
Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
When added to standard doses of antianginal drugs, ranolazine increased exercise duration at trough drug levels compared with placebo after 12 weeks treatment. Although significant, the effect size was modest, but not uncommon in studies of patients with stable angina pectoris.
The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by the Independent Review Panel (IRP).
Download detailed advice143KB (PDF)
Medicine details
- Medicine name:
- ranolazine (Ranexa)
- SMC ID:
- 565/09
- Indication:
- As add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- IRP
- Status
- Not recommended
- Date advice published
- 12 November 2012